Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    • News

  • Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    • News

  • Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    • News

  • European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    • News

  • Harris Technology’s refurbished boom signals FY26 profit inflection
    Harris Technology’s refurbished boom signals FY26 profit inflection
    • News

Jindalee Signs Agreement to List McDermitt Lithium Project on NASDAQ

  • In News
  • April 13, 2026
  • Tim Grey
Jindalee Signs Agreement to List McDermitt Lithium Project on NASDAQ

Jindalee Lithium (ASX: JLL) has executed a binding Business Combination Agreement with Constellation Acquisition Corp I to establish US Elemental Inc. as a NASDAQ listed company holding its US assets, including the McDermitt Lithium Project in Oregon. The transaction represents a key step in accessing US capital markets to support development of one of the largest lithium resources in the United States.

Strategic Pathway to US Listing
The agreement will see Jindalee’s US subsidiary, HiTech Minerals, become part of US Elemental, which is expected to list on NASDAQ upon completion. Jindalee is expected to retain a majority interest in the new entity, maintaining exposure to the McDermitt Project while unlocking a dedicated US-listed vehicle.

The proposed transaction implies a pro forma enterprise value of approximately US$571 million, reflecting the scale and strategic importance of the Company’s US lithium assets.

Jindalee Lithium Managing Director and CEO Ian Rodger commented:

“Execution of the Business Combination Agreement represents a key milestone in advancing our strategy to access US capital markets to support development of the McDermitt Project. The proposed Transaction and US listing of US Elemental is expected to improve our ability to fund the next phase of work, including infill drilling, advanced metallurgical optimisation and feasibility level studies.”

Funding to Support Project Advancement
The transaction includes plans for a capital raise to support the next phase of development, alongside a binding funding commitment from an affiliate of Constellation’s sponsor, Antarctica Capital. Initial funding will be available immediately, with additional capital expected at completion.

This funding pathway is designed to support ongoing work programs, including drilling, metallurgical optimisation, and feasibility studies.

Positioned to Benefit from US Lithium Demand
The McDermitt Project is one of the largest lithium resources in the US and is strategically positioned to benefit from growing demand for battery materials and increasing government support for domestic supply chains.

The establishment of a US-listed platform is expected to enhance Jindalee’s ability to attract capital and progress development in line with market demand.

Advancing Toward Development
Completion of the transaction remains subject to customary approvals and conditions, including shareholder approvals and minimum funding requirements. Upon completion, US Elemental is expected to provide a dedicated platform to advance its McDermitt Project and broader US strategy.

Positioned for Growth
The transaction strengthens Jindalee’s funding and development pathway while retaining majority ownership of its flagship asset. The NASDAQ listing is expected to increase visibility and provide access to a deeper pool of capital, supporting the long-term development of the McDermitt Lithium Project.

  • About
  • Latest Posts
Tim Grey
Latest posts by Tim Grey (see all)
  • AML3D announces stronger FY26, with positive EBITDA reported in the second half - September 1, 2026
  • Imagion Biosystems Advances MagSense® Phase 2 Trial - August 27, 2026
  • Acrux-developed Menopause Hormone Therapy to enter Australian market - May 28, 2026
  •  
  •  
  •  
  •  
  • (ASX: JLL)
  • Jindalee Lithium
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Tim Grey
Latest posts by Tim Grey (see all)
  • AML3D announces stronger FY26, with positive EBITDA reported in the second half - September 1, 2026
  • Imagion Biosystems Advances MagSense® Phase 2 Trial - August 27, 2026
  • Acrux-developed Menopause Hormone Therapy to enter Australian market - May 28, 2026

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Tim Grey
Latest posts by Tim Grey (see all)
  • AML3D announces stronger FY26, with positive EBITDA reported in the second half - September 1, 2026
  • Imagion Biosystems Advances MagSense® Phase 2 Trial - August 27, 2026
  • Acrux-developed Menopause Hormone Therapy to enter Australian market - May 28, 2026
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.